Novartis 2019 revenue: $47.45 billion 2018 revenue: $44.75 billion Headquarters: Basel, Switzerland. Sales for breast-cancer drug Kisqali soared 49% year over year on a constant-currency basis to $159 million. This excludes both the Alcon and Sandoz U.S. oral solids and dermatology business, as well as the introduction of generic competition to Gilenya and Sandostatin, it said.Sales of Zolgensma, a one-shot treatment for infant spinal muscular atrophy and which is now the world’s most expensive drug, totaled $186 million, an increase from $160 million which Novartis reported in the third quarter, but a little below the $196 million forecast by analysts at Jefferies.Novartis AG said Wednesday that net income fell 5.9% in the final quarter of the year, hit by tax charges, but guided for growth in both sales and profit in 2020.The continued momentum of its drugs Entresto and Cosentyx, combined with the launch of gene-therapy Zolgensma, helped drive growth at the topline, the pharmaceutical major said.Novartis attributed the fall in reported profit to higher taxes, including a one-time deferred tax expense. Sales for spinal muscular atrophy gene therapy Zolgensma skyrocketed to $205 million thanks to increased screening of newborns in the U.S. Heart failure drug Entresto was another big winner in Q2, with sales jumping 40% on a constant-currency basis to $580 million.Stock Advisor launched in February of 2002. Novartis Gross profit (FY, 2017) 31.9 B. Novartis Gross profit margin (FY, 2017), % 65%. In 2018, Swiss-based Novartis was the third largest pharmaceutical company worldwide based on revenue from prescription drugs.In 2019, Novartis made some 47 billion U.S. dollars of revenue … And while sales for autoimmune-disease drug Cosentyx rose 12% on a constant-currency basis to $944 million, the drug's growth was held back somewhat by the effects of the COVID-19 outbreak on dermatology and rheumatology practices.The company attributed its IFRS net income decline primarily to higher impairments. Novartis kept things busy in 2019 as it continued to focus on … Follow her on Twitter @bkollmeyer. Download prior years of the Novartis Annual Review, and the Annual Report and Form 20-F, which contain our complete audited financial statements. But Novartis projects that its core operating income will increase in full-year 2020 by a low double-digit percentage.Novartis announced non-IFRS core net income of $3.1 billion, or $1.36 per share. NOVN.SW Mkt cap, 21-Jul-2020.
Novartis AG net income for the quarter ending June 30, 2020 was $1.867B , a 72.54% decline year-over-year. One late-stage program for which Novartis has high hopes is Entresto in treating heart failure with preserved ejection fraction (HFpEF). Potential U.S. Food and Drug Administration approval is expected in the first half of 2021.Novartis had several bright spots in the second quarter, though.